Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9721049rdf:typepubmed:Citationlld:pubmed
pubmed-article:9721049lifeskim:mentionsumls-concept:C1882598lld:lifeskim
pubmed-article:9721049lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:9721049lifeskim:mentionsumls-concept:C0023688lld:lifeskim
pubmed-article:9721049lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:9721049lifeskim:mentionsumls-concept:C0475264lld:lifeskim
pubmed-article:9721049lifeskim:mentionsumls-concept:C0259952lld:lifeskim
pubmed-article:9721049lifeskim:mentionsumls-concept:C0534468lld:lifeskim
pubmed-article:9721049pubmed:issue1lld:pubmed
pubmed-article:9721049pubmed:dateCreated1998-10-29lld:pubmed
pubmed-article:9721049pubmed:abstractTextIn rat whole brain homogenates, saturation binding analysis revealed that both [3H]2-BFI (2-(2-benzofuranyl)-2-imidazoline) and [3H]idazoxan (in the presence of 5 microM rauwolscine) bound with high affinity to an apparent single population of sites. However, the Kd for [3H]2-BFI (1.74+/-0.14 nM) was significantly (P < 0.01) less than that for [3H]idazoxan (10.4+/-2.68 nM). In competition studies idazoxan, 2-BFI, BU224 (2-(4,5-dihydroimidaz-2-yl)-quinoline), amiloride and guanabenz displayed high affinity (Ki values = 7.32, 1.71, 2.08, 21.80 and 14.90 nM, respectively) for 70-80% of sites, and low microM affinity for the remaining 20-30% of sites labelled by [3H]2-BFI. In contrast, several alpha2-adrenoceptor, imidazoline I1 receptor and histamine receptor ligands exhibited only micromolar affinity for the [3H]2-BFI labelled site. Quantitative receptor autoradiography revealed high binding by [3H]2-BFI to discrete brain nuclei, notably the area postrema, interpeduncular nucleus, arcuate nucleus, mammillary peduncle, ependyma and pineal gland. These data indicate that [3H]2-BFI recognises imidazoline I2 receptors in rat brain with higher affinity and selectivity than [3H]idazoxan and thus represents a superior radioligand to [3H]idazoxan for the study of imidazoline I2 receptors.lld:pubmed
pubmed-article:9721049pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9721049pubmed:languageenglld:pubmed
pubmed-article:9721049pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9721049pubmed:citationSubsetIMlld:pubmed
pubmed-article:9721049pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9721049pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9721049pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9721049pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9721049pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9721049pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9721049pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9721049pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9721049pubmed:statusMEDLINElld:pubmed
pubmed-article:9721049pubmed:monthJullld:pubmed
pubmed-article:9721049pubmed:issn0014-2999lld:pubmed
pubmed-article:9721049pubmed:authorpubmed-author:HudsonA LALlld:pubmed
pubmed-article:9721049pubmed:authorpubmed-author:NuttD JDJlld:pubmed
pubmed-article:9721049pubmed:authorpubmed-author:LioneL ALAlld:pubmed
pubmed-article:9721049pubmed:issnTypePrintlld:pubmed
pubmed-article:9721049pubmed:day17lld:pubmed
pubmed-article:9721049pubmed:volume353lld:pubmed
pubmed-article:9721049pubmed:ownerNLMlld:pubmed
pubmed-article:9721049pubmed:authorsCompleteYlld:pubmed
pubmed-article:9721049pubmed:pagination123-35lld:pubmed
pubmed-article:9721049pubmed:dateRevised2009-9-29lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:meshHeadingpubmed-meshheading:9721049-...lld:pubmed
pubmed-article:9721049pubmed:year1998lld:pubmed
pubmed-article:9721049pubmed:articleTitleCharacterisation and localisation of [3H]2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I2 receptors.lld:pubmed
pubmed-article:9721049pubmed:affiliationPsychopharmacology Unit, School of Medical Sciences, University of Bristol, UK.lld:pubmed
pubmed-article:9721049pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9721049pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:9721049pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9721049lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9721049lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9721049lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9721049lld:pubmed